Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overal... ( WAYNE N.J. and February 2007 Bay...)

HOME >> MEDICINE >> TECHNOLOGY

Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival

Date:6/14/2010

WAYNE, N.J. and EMERYVILLE, Calif., June 14 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving overall survival in the first-line setting. NExUS evaluated Nexavar versus placebo in combination with two chemotherapeutic agents, gemcitabine and cisplatin. A positive secondary endpoint of progression-free survival (PFS) was observed in the trial. The safety and tolerability of the treatment triplet was as expected and did not show any new or unexpected toxicities. Data from this study are expected to be presented at an upcoming scientific meeting.

Nexavar is currently marketed worldwide for the treatment of hepatocellular carcinoma (HCC), or liver cancer, and advanced renal cell carcinoma (RCC), or kidney cancer.

Enrollment in NExUS commenced in February 2007. In 2008, based on the results seen in a previous Nexavar first-line NSCLC Phase 3 trial, the NExUS study protocol was amended to stop enrolling and treating squamous cell carcinoma patients. Of the squamous cell patients who were enrolled in the NExUS trial before the amendment, a higher mortality was observed. This finding was consistent with what was seen in the previous trial.

Bayer and Onyx will further review the findings of this analysis to det
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
7. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
11. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye

Post Your Comments:

(Date:5/17/2013)... , May 17, 2013 Orexigen® Therapeutics, Inc. (Nasdaq: ... a company overview at the UBS Global Healthcare Conference in ... for Wednesday, May 22 nd at 11 a.m. Eastern ... of the presentation, please visit the Investor Relations section of ... will be available for 14 days after the event. ...

(Date:5/17/2013)... 17, 2013 Sony Biotechnology Inc. ("Sony") today announced the ... and 130um sorting chip. Sony will also be exhibiting its ... SH800 Cell Sorter, the EC800 flow cytometer, and new SP6800 ... 2013, which will be held at the San ... California , from May 20 - 22. ...

(Date:5/17/2013)... -- Research explores data on treatments ... to be presented Shire ... global specialty biopharmaceutical company, announces that it will present ... Psychiatric Association (APA) 166th Annual Meeting in ... presented represent Shire,s ongoing commitment to the clinical research ...

[0] Orexigen Therapeutics to Present at the UBS Global Healthcare Conference [0] Sony Delivers New Technology for Science to CYTO 2013 [0] Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting

... Ontario, Sept. 2, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... members of its senior management team will be participating at ... and Chief Executive Officer will make a presentation at the ... London on Thursday, September 15, 2011 at 10:35 a.m. BT ...

... Lifetime Products, Inc. -- a worldwide Utah-based manufacturer ... storage sheds, and lawn and garden products -- announced ... adding a new Health and Wellness product category. ... will feature products like the award-winning Lifetime Tru-Motion™ ...

Cached Medicine Technology:Lifetime Products Enters New Product Category: Health and Wellness 2

Valeant Pharmaceuticals to Present at Industry Conferences Lifetime Products Enters New Product Category: Health and Wellness

(Date:5/20/2013)... ESMO 32nd ESTRO European Cancer Congress will take ... ), from Friday 17 September to Tuesday 1 October ... The congress will build on the success of the ... Medical Oncology) and ESTRO (European Society for Therapeutic Radiology ... in Europe to offer presentations of cutting-edge research across ...

(Date:5/20/2013)... 2013 Ariosa Diagnostics, maker of the ... syndrome and other chromosome conditions, has announced today the ... conceived or conceived using the patient’s own egg. ... analysis as an option to those women electing to ... the evaluation of fetal sex and sex chromosome genetic ...

(Date:5/20/2013)... Soliant Health, a leading specialty healthcare staffing provider ... its fifth annual Most Beautiful Hospitals in the U.S. contest. ... decided to bypass its routine selection process and include not ... be in the running for the 2013 Most Beautiful Hospitals ... and runs through June 23. Winners will be revealed on ...

(Date:5/20/2013)... Cayman, Cayman Islands (PRWEB) May 20, 2013 ... knowledge-based, high tech Special Economic Zone in the ... Referral Network, an initiative to grow the zone’s ... with Cayman’s business-friendly environment and tax benefits are ... many of them referrals from zone channel partners. ...

(Date:5/20/2013)... Jointly established by The Hong ... (Sichuan U), China's first Institute for Disaster ... officially opened. Both institutions also held the ... Reduction" to conclude lessons learnt from Wenchuan ... Margareta Wahlström, Special Representative of the Secretary-General ...

[0] Media registration for the European Cancer Congress [0] Ariosa Diagnostics Expands Harmony Prenatal Test to Twin Pregnancies and Launches New X,Y Analysis Test [0] Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S.[0] Cayman Enterprise City Introduces Referral Network [0] PolyU and Sichuan U Jointly Set Up China's First Institute for Disaster Management and Reconstruction

... identified a possible cause for the loss of a tumour ... development of more aggressive forms of prostate cancer. , ... prostate cancer develops because we now have some insight into ... Jeremy Squire, a professor in the Department of Pathology and ...

... HPV infection is more common among men than women, explaining ... HPV related head and neck cancer, according to a study ... by AHNS, ASCO, ASTRO and SNM., Human papillomavirus, or HPV, ... neck cancer that are becoming more prominent in the United ...

... or without chemotherapy is less effective for patients with HIV ... patients who do not have HIV, according to a study ... by AHNS, ASCO, ASTRO and SNM. , Treating head and ... Because of the advancements in treating HIV, these patients are ...

... of positron emission tomography/computed tomography (PET/CT) scans in head ... before they become clinically apparent and may improve the ... presented at the Multidisciplinary Head and Neck Cancer Symposium, ... is a relatively new test and its use as ...

... HOUSTON Scientists have connected two signature characteristics of pancreatic ... a new potential target for drugs to treat one of ... in the journal Cancer Cell and led by ... connected the molecular dots between: Mutated versions ...

... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... developing high blood pressure, diabetes or other risk factors for ... attack or stroke by age 80 than their less healthy ... to middle age with an optimal profile, it,s really like ...

Cached Medicine News:Health News:Oral HPV infection, HPV-related cancers more common in men 2 Health News:Standard treatments for head and neck cancer less effective in HIV-positive patients 2 Health News:Mutated Kras spins a molecular loop that launches pancreatic cancer 2 Health News:Mutated Kras spins a molecular loop that launches pancreatic cancer 3 Health News:Optimal Heart Health Starts Early: Study 2 Health News:Optimal Heart Health Starts Early: Study 3

New Queen's University research sheds light on gene destruction linked to aggressive prostate cancer Oral HPV infection, HPV-related cancers more common in men Standard treatments for head and neck cancer less effective in HIV-positive patients Routine follow-up scans can detect head and neck cancer recurrences earlier Mutated Kras spins a molecular loop that launches pancreatic cancer Optimal Heart Health Starts Early: Study

Spetzler titanium microsurgical instrument. Small spatula dissector, bayonet, angled up 30°....

Instrument for transphenoidal hypophysectomy, bayonet-shaped, dissector, sharp inner edge, left....

Cushing-landolt bi-valve speculum for trans-sphenoidal hypophysectomie....

Hardy pituitary spoon, bayonet, malleable....

Medicine Products:

Small Spatula Dissector Hardy Dissector Cushing-Landolt Bi-valve Speculum Hardy Pituitary Spoons